Other languages Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
19.97 ^USD	-2.96%		-9.64%	-28.81%

May. 09	Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating	MT
May. 08	Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pharvaris N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08
Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024	May. 08
Pharvaris Narrows Q4 Net Loss; Hires New CFO	Apr. 10
Pharvaris N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10
Pharvaris Says FDA Lifts Clinical Hold on Application for Potential Treatment of Hereditary Angioedema Attacks	Jan. 22
Correction: Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Jan. 22
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Jan. 22
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks	Jan. 22
Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023	Dec. 08
Koersalarm: aandeel Pharvaris blijft stijgen	Dec. 07
Sector Update: Health Care Stocks Mixed Premarket Wednesday	Dec. 06
Sector Update: Health Care	Dec. 06
Pharvaris' Phase 2 Study of Deucrictibant Meets Primary Endpoint; Prices $300 Million Offering; Shares Jump 42% Pre-Bell	Dec. 06
Top Premarket Gainers	Dec. 06
Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks	Dec. 06
Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer	Nov. 15
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting	Nov. 09
Pharvaris N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02
Pharvaris N : Early symptom relief following treatment with the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks (German) à link to Magerl	23-09-04
Pharvaris N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pharvaris N.V.

Equities

PHVS

NL00150005Y4

Other languages

Filters